Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable Suspension [Phase 1]

View source ↗

Summary

Phase 1 study of HNC364 Injectable Suspension in Parkinson's disease has completed; no detailed results are provided in the snippet.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• HNC364 Injectable Suspension (HNC364)

Snippet

Sponsor: Guangzhou Henovcom Bioscience Co. Ltd. | Conditions: Parkinson's Disease | Phase 1 | Status: COMPLETED